-
-
-
-
-
-
-
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing
-
-
-
-
-
-
-
Aditxt subsidiary Adimune plans FDA trials for autoimmune treatments
-
-
-
-
-
-
-
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
-
-
-
-
-
-
-
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
-
-
-
-
-
-
-
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary
-
-
-
-
-
-
-
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
-
-
-
-
-
-
-
Aditxt, Inc (ADTX) Announces 1:250 Reverse Share Split
-
1,157,986 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

